A mid-stage trial of the vaccine in South Africa, where a troubling new variant of the virus is common, showed 60% effectiveness among people who did not have HIV. Novavax shares surged 34% in after hours trading following release of the trial results on the same day the United States reported its first cases of the South African variant.
No comments:
Post a Comment